NASDAQ:ATHA Athira Pharma (ATHA) Stock Price, News & Analysis $0.64 -0.02 (-3.02%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Athira Pharma Stock (NASDAQ:ATHA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Athira Pharma alerts:Sign Up Key Stats Today's Range$0.63▼$0.6650-Day Range$0.42▼$0.8052-Week Range$0.41▼$4.30Volume191,578 shsAverage Volume14.16 million shsMarket Capitalization$24.83 millionP/E RatioN/ADividend YieldN/APrice Target$13.83Consensus RatingHold Company OverviewAthira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Read More… Former Trump advisor releases terrifying warning (Ad)Goldman Sachs: 300 Million People Are At Risk The mainstream media are practically ignoring the most important financial story of the decade. Goldman Sachs, the IMF, JP Morgan, Bank of America, and Morgan Stanley have issued warnings. Yet most ordinary Americans have no idea. Now one former Trump advisor is sounding the alarm. “If people knew the full facts, there’d be blood in the streets.” Get the facts and learn how to protect your family now. Athira Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks56th Percentile Overall ScoreATHA MarketRank™: Athira Pharma scored higher than 56% of companies evaluated by MarketBeat, and ranked 495th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingAthira Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAthira Pharma has only been the subject of 4 research reports in the past 90 days.Read more about Athira Pharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Athira Pharma are expected to grow in the coming year, from ($2.35) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Athira Pharma is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Athira Pharma is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAthira Pharma has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Athira Pharma's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.38% of the float of Athira Pharma has been sold short.Short Interest Ratio / Days to CoverAthira Pharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Athira Pharma has recently decreased by 0.64%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAthira Pharma does not currently pay a dividend.Dividend GrowthAthira Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.38% of the float of Athira Pharma has been sold short.Short Interest Ratio / Days to CoverAthira Pharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Athira Pharma has recently decreased by 0.64%, indicating that investor sentiment is improving. News and Social Media1.1 / 5News SentimentN/A Search Interest4 people have searched for ATHA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows2 people have added Athira Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Athira Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,033.00 in company stock.Percentage Held by Insiders19.80% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Athira Pharma's insider trading history. Receive ATHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ATHA Stock News HeadlinesAthira Pharma’s Regulatory Compliance Challenges Threaten Drug Development PipelineNovember 9, 2024 | tipranks.comAthira exploring strategic alternatives after Alzheimer’s failureNovember 8, 2024 | finance.yahoo.comJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.November 24, 2024 | Priority Gold (Ad)JMP Securities Keeps Their Hold Rating on Athira Pharma (ATHA)November 8, 2024 | markets.businessinsider.comAthira Pharma Reports Q3 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comAthira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business UpdatesNovember 7, 2024 | globenewswire.comUS Penny Stocks: November 2024's Top Picks To ConsiderNovember 4, 2024 | finance.yahoo.comAthira Pharma (NASDAQ:ATHA) Stock Quotes, Forecast and News SummaryNovember 3, 2024 | benzinga.comSee More Headlines ATHA Stock Analysis - Frequently Asked Questions How have ATHA shares performed this year? Athira Pharma's stock was trading at $2.43 at the beginning of the year. Since then, ATHA stock has decreased by 73.6% and is now trading at $0.6420. View the best growth stocks for 2024 here. How were Athira Pharma's earnings last quarter? Athira Pharma, Inc. (NASDAQ:ATHA) issued its earnings results on Thursday, November, 7th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.05. When did Athira Pharma IPO? Athira Pharma (ATHA) raised $160 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel acted as the underwriters for the IPO and JMP Securities was co-manager. Who are Athira Pharma's major shareholders? Top institutional investors of Athira Pharma include GSA Capital Partners LLP (1.03%) and Bristlecone Advisors LLC (0.88%). Insiders that own company stock include Perceptive Advisors Llc, Glenna Mileson, Mark James Litton, Andrew Gengos, Kelly A Romano, Hans Moebius, Mark Worthington, Rachel Lenington and James A Johnson. View institutional ownership trends. How do I buy shares of Athira Pharma? Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Athira Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Athira Pharma investors own include Palantir Technologies (PLTR), Pfizer (PFE), PayPal (PYPL), Advanced Micro Devices (AMD), Alibaba Group (BABA), Intel (INTC) and Meta Platforms (META). Company Calendar Last Earnings11/07/2024Today11/24/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/27/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATHA CUSIPN/A CIK1620463 Webathira.com Phone425-620-8501FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$13.83 High Stock Price Target$22.00 Low Stock Price Target$0.50 Potential Upside/Downside+2,054.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-115.62% Return on Assets-88.94% Debt Debt-to-Equity RatioN/A Current Ratio2.95 Quick Ratio2.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book0.43Miscellaneous Outstanding Shares38,669,000Free Float31,013,000Market Cap$24.83 million OptionableOptionable Beta2.82 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:ATHA) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.